Fondaparinux Injectable Product

Phase 3

QQueen Mary University of London

Fondaparinux Injectable Product is one of 3 therapeutic programs targeting Thrombosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ThrombosisRecruiting

ThrombosisPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Thrombosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Phase 3

5 2

Xarelto

WWim Janssens

Phase 3

1 3

Fondaparinux Injectable Product

QQueen Mary University of London

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Thrombosis

NCT06370273

Clinical

Trials by Indication[1]

Thrombosis1 trial

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

Recruiting·QQueen Mary University of London·Phase 3·NCT06370273·10,044 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fondaparinux Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Fondaparinux Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Queen Mary University of London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: QQueen Mary University of London

Fondaparinux Injectable Product

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Thrombosis1 trial

References

Drug Info

Quick Facts

Related News